For moderate to severe patients 12+ years not adequately controlled with other systemic drugs, including biologics.1


ONCE-DAILYNumber 1 prescribed oral JAK inhibitor for AD.


*As of 9/2023. Source: Integrated Symphony Health (PatientSource) and IQVIA (NSP). 

Josh, real RINVOQ patient.

“One pill once a day—that’s one of the things I love about RINVOQ.”

—real RINVOQ patient


RINVOQ is an oral JAK inhibitor for refractory, moderate to severe AD1


  • For patients 12+ weighing at least 88 lb (40 kg), initiate therapy with 15 mg once-daily
  • For patients ≥65 years of age, patients receiving strong CYP3A4 inhibitors, and patients with severe renal impairment (eGFR 15 to <30 mL/min/1.73 m2), the recommended dose of RINVOQ is 15 mg once-daily
  • RINVOQ is not recommended for use in patients with end-stage renal disease (eGFR <15 mL/min/1.73 m²), severe hepatic impairment (Child-Pugh C), or those receiving strong CYP3A4 inducers
  • RINVOQ initiation is not recommended in patients with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1,000 cells/mm3, or hemoglobin level less than 8 g/dL


For patients 12 to <65 years of age weighing at least 88 lb (40 kg):

  • If an adequate response is not achieved, consider increasing dosage to 30 mg once-daily
  • Discontinue RINVOQ if an adequate response is not achieved with the 30 mg dose
  • Use the lowest effective dose needed to maintain response


  • RINVOQ tablets should be taken orally with or without food
  • Advise patients to avoid food or drink containing grapefruit during treatment with RINVOQ
  • RINVOQ is an extended-release tablet; do not split, crush, or chew. Ensure tablet is swallowed whole

AD=atopic dermatitis.

RINVOQ® (upadacitinib) pills.


  • RINVOQ treatment should be interrupted if a patient develops a serious infection until the infection is controlled
  • Interruption of dosing may be needed for management of laboratory abnormalities. See monitoring and treatment considerations

AD=atopic dermatitis.

Want to learn about rapid skin clearance patients can see? In clinical studies
of RINVOQ, many patients achieved EASI 75 and vIGA 0/1 at Week 16.1

Itching to see more? See what patients experienced with RINVOQ in clinical trials.

Are your patients seeking treatment for the rash of atopic dermatitis?

Is itch a primary concern?

Safety is important to you. Want to know more about the safety profile of RINVOQ?

Want to know more about monitoring guidelines for RINVOQ?

RINVOQ Complete can help patients get the support they need to start
and stay on track with their prescribed treatment.

Familiar with Complete? RINVOQ Complete offers the same exceptional
AbbVie support you know and trust.

Enroll patients in

RINVOQ® Complete.
to help them get the support and resources they need
to get started and stay on track with RINVOQ

Need RINVOQ samples or want to request an appointment with a Rep?